Drugs / ACE527
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00901654 | Jun → Nov 2009 | — | TD Vaccines A/S | Completed | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT01739231 | Sep 2012 → Oct 2013 | diarrheal disease | PATH | Completed | Met primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT01060748 | Mar → Oct 2010 | diarrheal disease | TD Vaccines A/S | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACE527 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01739231 ↗ |
| Modality | Vaccine | “live attenuated, oral vaccine ACE527” NCT00901654 ↗ |
| Route | Oral | “live attenuated, oral vaccine ACE527” NCT00901654 ↗ |